Clinical Trial: An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)

U.S., Jan. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07365332) titled 'An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)' on Jan. 22.

Brief Summary: This is an adaptive, 2-part, randomized, multicenter, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy and safety of IKT-001 in adult participants with WHO Group 1 PAH.

Study Start Date: March, 2026

Study Type: INTERVENTIONAL

Condition: Pulmonary Arterial Hypertension

Intervention: DRUG: IKT-001

IKT-001 tablets for PO administration

DRUG: Placebo

Placebo to IKT-001 tablets for PO administration

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Inhibikase Therapeutics

Disclaimer: Curate...